Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.

Trial Profile

Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Dacomitinib (Primary)
  • Indications Penile cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Results (n=28), presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 08 Mar 2017 Planned End Date changed from 1 Apr 2016 to 15 Feb 2018.
    • 08 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 15 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top